Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
An update from Hansa Biopharma AB ( (SE:HNSA) ) is now available.
Hansa Biopharma has appointed Maria Törnsén as Chief Operating Officer and President U.S., effective May 19, 2025. With over 20 years of experience in global and U.S. operations, Törnsén’s expertise in rare diseases and gene therapy is expected to drive the company’s growth and profitability, particularly in the U.S. market. Her appointment comes as Hansa prepares for the next phase of development, including the growth of its IDEFIRIX product and anticipated catalysts in late 2025.
The most recent analyst rating on (SE:HNSA) stock is a Buy with a SEK175.00 price target. To see the full list of analyst forecasts on Hansa Biopharma AB stock, see the SE:HNSA Stock Forecast page.
More about Hansa Biopharma AB
Hansa Biopharma AB is a commercial-stage biopharmaceutical company focused on developing and commercializing innovative treatments for rare immunological conditions. The company utilizes its proprietary IgG-cleaving enzyme technology platform to address unmet medical needs in autoimmune diseases, gene therapy, and transplantation. Its portfolio includes imlifidase, an IgG antibody-cleaving enzyme therapy for kidney transplantation, and HNSA-5487, a next-generation IgG cleaving molecule.
Average Trading Volume: 201,271
Current Market Cap: SEK1.76B
Learn more about HNSA stock on TipRanks’ Stock Analysis page.